scholarly journals Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome

2020 ◽  
Vol 2020 ◽  
pp. 1-16
Author(s):  
Anna S. Huerta-Delgado ◽  
Daniel N. Roffe-Vazquez ◽  
Adrian M. Gonzalez-Gil ◽  
José R. Villarreal-Calderón ◽  
Oscar Tamez-Rivera ◽  
...  

The prevalence of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) has increased in the pediatric population. Irisin, an adipomyokine, is involved in white adipose tissue browning, energy expenditure, insulin sensitivity, and anti-inflammatory pathways. Data on the associations among circulating irisin levels, soluble cell adhesion molecules (sCAMs), and inflammatory cytokines is scarce in children and adolescents with MetS and T2DM. Subjects aged 6-16 years were grouped into T2DM, MetS, and healthy controls. Serum irisin levels were significantly lower in the MetS (6.6 [2.8-18.0] ng/mL) and T2DM (6.8 [2.2-23.2] ng/mL) groups compared with controls (30.3 [24.6-57.1] ng/mL). Negative correlations between irisin and the BMI percentile (R=−0.358), WC percentile (R=−0.308), and triglycerides (R=−0.284) were identified, while positive associations with TC (R=0.287), HDL-c (R=0.488), and LDL-c (R=0.414) were observed. Significant negative correlations were found between irisin and sNCAM (R=−0.382), sICAM-2 (R=−0.300), sVCAM-1 (R=−0.292), MCP-1 (R=−0.308), and IFN-α2 (R=−0.406). Of note, lower concentrations of most sCAMs (sICAM-1, sPSGL-1, sP-selectin, sEpCAM, sICAM-2, sALCAM, sPECAM-1, sCD44, sVCAM-1, sICAM-3, sL-selectin, and sNCAM) were shown in T2DM subjects compared with MetS patients. Lower irisin levels induce a lack of inhibition of oxidative stress and inflammation. In T2DM, higher ROS, AGEs, glucotoxicity, and inflammation trigger endothelial cell apoptosis, which downregulates the sCAM expression as a compensatory mechanism to prevent further vascular damage. In opposition, in subjects with MetS that have not yet developed T2DM and its accompanying stressors, the upregulation of the sCAM expression is ensued.

2017 ◽  
Vol 126 ◽  
pp. 151-159 ◽  
Author(s):  
América L. Miranda-Lora ◽  
Jenny Vilchis-Gil ◽  
Mario Molina-Díaz ◽  
Samuel Flores-Huerta ◽  
Miguel Klünder-Klünder

2021 ◽  
Vol 19 (3) ◽  
pp. 122-125
Author(s):  
Rohit Chordia ◽  

Background: Comorbidities are important events in the natural history of the disease and have a negative effect on the morbidity and mortality of COPD patients. It is increasingly recognized that, many patients with COPD have co-morbidities that have a major impact on quality of life and survival. Present study aims at studying the prevalence and effects of comorbidities in COPD patients at a tertiary hospital. Material and Methods: Present study was cross sectional, observational study conducted in COPD patients, diagnosed for more than 5 years, underwent investigations for various comorbidities. Results: In present study, 130 COPD patients were studied for various co-morbidities. Majority of cases were from 50 -64 years age group (49.23 %) and were male (97.69 %). Smoking was major factor noted among cases (73.85 %), out of them 23.96 % were current smoker. Mean duration since quitting of smoking was 7.24 ± 5.83 years. Comorbidities noted in present study were systemic hypertension (42.31 %), GERD and gastric ulceration (31.54 %), type 2 diabetes mellitus (30.77 %), metabolic syndrome (29.23 %), anemia (11.54 %), left sided cardiac abnormalities (10.77 %), depression (8.46 %), obstructive sleep apnea (6.92 %), ischemic heart disease (6.15 %), osteoporosis (4.62 %), bronchiectasis (2.31 %) and lung cancer (0.77 %). Conclusion: Comorbidities noted in present study were hypertension, GERD, type 2 diabetes mellitus, metabolic syndrome, anaemia, left sided cardiac abnormalities and depression.


Sign in / Sign up

Export Citation Format

Share Document